Tradipitant Improves Nausea Associated with Gastroparesis

 

While medications and surgery can both improve gastroparesis symptoms, many patients still struggle with finding the right treatment. However, a new medication might soon help: tradipitant. In a study published in Gastroenterology, researchers explored whether tradipitant could improve patient outcomes and reduce symptoms for patients with either the idiopathic or diabetic form of the condition.

Gastroparesis

Although doctors aren’t sure of the exact cause of gastroparesis, many believe it relates to a damaged vagus nerve. This damage can come from surgical complications or too much glucose in your blood. Gastroparesis is a disorder which alters the way food moves from your stomach to the small intestine. Normally, gastrointestinal muscles squeeze and relax; this movement pushes food out of the stomach. In patients with gastroparesis, the muscles fail to perform this rhythm. As a result, it is difficult to move food through the digestive system.

Symptoms include:

  • Nausea and vomiting
  • Acid reflux
  • Loss of appetite
  • Abdominal pain
  • Bloating
  • Commonly feeling full
  • Heartburn
  • Indigestion

Learn more about gastroparesis here.

Tradipitant

Within the study, researchers tracked 152 patients with gastroparesis over a 2 year period. The trial was double-blind. This means that patients received either tradipitant or a placebo, but neither patients nor administers knew what the patient was receiving.

Out of the participants, 77 patients received 85mg tradipitant 2 times daily, while 75 received a placebo. Patients took their medication for 1 month. During this time, data was collected via questionnaires, diaries, and index scores. Ultimately, researchers sought to understand how tradipitant impacted symptoms such as nausea and vomiting.

First, researchers noted that patients taking tradipitant experienced less nausea, and more nausea-free days, than those taking a placebo. 32.9% of patients using tradipitant expressed a nausea score under 1 by the end of the month. Alternately, only 11.8% of those taking the placebo experienced the same result.

Read the source article here.

Jessica Lynn

Jessica Lynn

Jessica Lynn has an educational background in writing and marketing. She firmly believes in the power of writing in amplifying voices, and looks forward to doing so for the rare disease community.

Share this post

Share on facebook
Share on google
Share on twitter
Share on linkedin
Share on pinterest
Share on print
Share on email